Low Risk Myelodysplastic Syndromes Completed Phase 2 Trials for Bemcentinib (DB12411)

Also known as: Low Risk Myelodysplastic Syndrome / Low-risk Myelodysplastic Syndrome

IndicationStatusPhase
DBCOND0147387 (Low Risk Myelodysplastic Syndromes)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03824080Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesTreatment